EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieÄquivalenzstudieMultizentrische StudieOpen Access

HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse

Kristen M Marks, Minhee Kang, Triin Umbleja, Andrea Cox, Karen J Vigil, Ngan T Ta, Ayotunde Omoz-Oarhe, Hugo Perazzo, Josphat Kosgei, Timothy Hatlen, Jennifer Price, Leolin Katsidzira und 6 weitere

JAMA · 2025

DOI: 10.1001/jama.2024.24490 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JAMA, 2025. Verfasst von Kristen M Marks und 17 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medicine, New York, New York. Hauptthemen laut MEDLINE: Adjuvants, Immunologic, Hepatitis B, Hepatitis B Vaccines, HIV Infections. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Nonresponse to hepatitis B vaccine is common among people with HIV, resulting in vulnerability to infection with hepatitis B virus (HBV).

Objective

To compare the seroprotection response achieved with a 2-dose (noninferiority, 10% margin) and a 3-dose hepatitis B vaccine with a cytosine phosphoguanine adjuvant (HepB-CpG vaccine) vs a conventional 3-dose hepatitis B vaccine with an aluminum hydroxide adjuvant (HepB-alum vaccine) in people with HIV and prior nonresponse to HepB-alum vaccine. Design, Setting, and Participants This phase 3, open-label, randomized clinical trial included people with HIV receiving antiretroviral therapy (CD4 cell count ≥100 cells/μL and HIV RNA <1000 copies/mL) without past or present serological evidence of having HBV or a response to hepatitis B vaccine. From December 2020 to February 2023, 561 adults were enrolled in the study at 41 sites in 10 countries in Africa, Asia, North America, and South America with follow-up for the primary outcome analysis through September 4, 2023.

Interventions

Participants were randomly assigned to receive 2 doses of HepB-CpG vaccine administered intramuscularly at weeks 0 and 4; 3 doses of HepB-CpG vaccine administered intramuscularly at weeks 0, 4, and 24; or 3 doses of HepB-alum vaccine administered intramuscularly at weeks 0, 4, and 24. Main Outcomes and Measures The primary outcome was a seroprotection response to hepatitis B vaccine (defined as level of antibody titer against hepatitis B surface antigen [HBsAg] ≥10 mIU/mL) at week 12 for the 2-dose regimen (8 weeks after dose 2) and at week 28 for 3-dose regimens (4 weeks after dose 3). Key secondary outcomes included seroprotection response at additional time points, antibody titer against HBsAg, and adverse events within 4 weeks of hepatitis B vaccination.

Results

Of 561 participants included in the analysis (median age, 46 years [IQR, 31-56 years]); 64% were male; 17% of participants were Asian, 42% were Black, and 35% were White), a seroprotection response was achieved in 93.1% who received 2 doses of HepB-CpG vaccine (n = 174), in 99.4% who received 3 doses of HepB-CpG vaccine (n = 169), and in 80.6% who received 3 doses of HepB-alum vaccine (n = 165). The stratified difference in seroprotection response between the 2-dose HepB-CpG vaccine group and the 3-dose HepB-alum vaccine group was 12.5% (97.5% CI, 4.1%-20.9%), achieving noninferiority and indicating superiority. The 3-dose HepB-CpG vaccine regimen was superior to the 3-dose HepB-alum vaccine regimen (stratified difference in seroprotection response, 18.4% [repeated 97.5% CI, 10.4%-26.2%]). By week 12, more than 90% of participants who received HepB-CpG vaccine achieved a seroprotection response. The 3-dose regimen of HepB-CpG vaccine achieved a higher proportion of participants with antibody titer against HBsAg greater than 1000 mIU/mL (78.1%) vs the other 2 regimen groups (26.4% for 2 doses of HepB-CpG vaccine and 35.2% for 3 doses of HepB-alum vaccine). No unexpected safety issues were observed. Conclusions and Relevance Among people with HIV and nonresponse to prior hepatitis B vaccination, both the 2-dose and 3-dose regimens of HepB-CpG vaccine achieved a superior seroprotection response compared with 3 doses of HepB-alum vaccine. Trial Registration ClinicalTrials.gov Identifier: NCT04193189

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adjuvants, ImmunologicHepatitis BHepatitis B VaccinesHIV InfectionsAdultFemaleHumansMaleMiddle AgedAluminum HydroxideHepatitis B AntibodiesHepatitis B Surface AntigensInjections, IntramuscularImmunization ScheduleImmunogenicity, VaccineDinucleoside Phosphates

Substanzen

Adjuvants, ImmunologicAluminum HydroxideHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B VaccinesDinucleoside PhosphatesCpG dinucleotide

Autor:innen und Institutionen

  • Weill Cornell Medicine, New York, New York.
  • T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts.
  • School of Medicine, Johns Hopkins University, Baltimore, Maryland.
  • University of Texas, Houston.
  • Hanoi Medical University, Hanoi, Vietnam.
  • Botswana Harvard AIDS Institute Partnership, Gaborone.

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Marks, K. M., Kang, M., Umbleja, T., Cox, A., Vigil, K. J., Ta, N. T., Omoz-Oarhe, A., Perazzo, H., Kosgei, J., Hatlen, T., Price, J., Katsidzira, L., Supparatpinyo, K., Knowles, K., Alston-Smith, B. L., Rathod, P., Sherman, K. E., & ACTG 5379 (BEe-HIVe) Study Team (2025). HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse. JAMA. https://doi.org/10.1001/jama.2024.24490

Vancouver

Marks KM, Kang M, Umbleja T, Cox A, Vigil KJ, Ta NT, et al. HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse. JAMA. 2025. doi:10.1001/jama.2024.24490

BibTeX
@article{Marks2025,
  author = {Marks, Kristen M and Kang, Minhee and Umbleja, Triin and Cox, Andrea and Vigil, Karen J and Ta, Ngan T and Omoz-Oarhe, Ayotunde and Perazzo, Hugo and Kosgei, Josphat and Hatlen, Timothy and Price, Jennifer and Katsidzira, Leolin and Supparatpinyo, Khuanchai and Knowles, Kevin and Alston-Smith, Beverly L and Rathod, Parita and Sherman, Kenneth E and ACTG 5379 (BEe-HIVe) Study Team, ACTG 5379 (BEe-HIVe) Study Team},
  title = {HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse},
  journal = {JAMA},
  year = {2025},
  doi = {10.1001/jama.2024.24490}
}
Kostenlos starten →